In a multicenter , open-label , randomized , phase III study ( NCT@ ) , @ patients ( @ patients from the People 's Republic of China ) were randomized @:@ to receive either FOLFOX@ or doxorubicin until disease progression , intolerable toxicity , death , or surgical resection .